Revenues of $28.25 million in Q2’26, up 48.1% from Q2’25 Pharma revenue increased to $14.65 million, an increase of 88.9% versus...
Barchart Research What to Expect from PAYS Earnings PAYS Generated August 4, 2026 Current Price $9.28 EPS Estimate $$0.14 Consensus Rating Strong Buy Average Move 12.53% PaySign's Patient Affordability...
Paysign, Inc. (NASDAQ: PAYS ), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment...
Paysign, Inc. (NASDAQ: PAYS ), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment...
Paysign, Inc. (NASDAQ: PAYS ), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment...
Paysign (NASDAQ:PAYS) reported what executives described as the strongest start to a year in the company’s history, with first-quarter 2026 revenue rising 50.8% year over year to $28 million and profitability...
Mix Shift Continues to Deliver Expansion in Gross and Operating Margin Strong Balance Sheet Enables Continued Investment for Profitable Growth
Barchart Research What to Expect from PAYS Earnings PAYS Generated May 11, 2026 Current Price $6.69 EPS Estimate $$0.16 Consensus Rating Strong Buy Average Move 11.25% Paysign's Patient Affordability Momentum...
Paysign, Inc. (NASDAQ: PAYS ), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment...
Mix Shift Drives Gross and Operating Margin Expansion Strong Balance Sheet Enables Continued Investment for Profitable Growth